NY-ESO-1 SE T cells mediate potent and specific antitumor activity in vivo. (A) Human T-cell chimerism in mice peripheral blood, calculated as follows: % of hCD3^pos cells/ [(% of hCD3^pos + % of mCD45^pos cells) × 100], detected by flow cytometry. Mice had been injected with mock-transduced (mock-trd), TR and SE cells. Means and SEM are shown. *P <. 05 and **P < .01, by unpaired Student t test. (B) IFN-γ levels (pg/mL) detected in mice sera after infusion of mock-trd, TR, and SE cells. Means and SEM are shown. *P < .05 by 1-way ANOVA and Bonferroni’s multiple comparison test. (C) Body weight variations, expressed as % and calculated as follows: body weight at each time point/[basal body weight recorded before U266 cell infusion × 100]. The panels correspond to animals treated with medium only (U266), mock-trd, TR, and SE T cells. Body weight kinetics of control littermates is also shown (ctrl). Each single replicate is shown. Horizontal dotted lines indicate the mean % body weight at the time of T-cell infusion. (D) U266 MM chimerism in bone marrow, calculated as follows: % of hCD138^pos cells/[(% of hCD138^pos + % of mCD45^pos cells) × 100], detected by flow cytometry. Analyses of untreated mice (U266) and mock-trd, TR, and SE cells injected mice. Each single replicate, means, and SEM are shown. ***P < .005, by 1-way ANOVA and Bonferroni’s multiple comparison test. (E) Bioluminescence images of selected mice from the U266, mock-trd, TR, and SE T-cell treatment groups, obtained 1 week after treatment. A control mouse that did not receive either U266 or T cells is also included. (F) Noninvasive bioluminescence monitoring of MM growth in mice that received U266 but no T cells (purple dotted lines); mock-transduced T cells (red lines), NY-ESO-1 conventionally transferred T cells (blue lines), or NY-ESO-1 SE T cells (light green lines). Total flux expressed as photons/second and recorded from each mouse is shown.